Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Eisai Offers Indonesia 151 Million Tablets of Elephantiasis Drug for Free
October 6, 2015
- GSK to Seek COPD Indication for Relvar in January-March 2016
October 6, 2015
- Belsomra Most Heavily Pitched Drug in July: Anterio Ranking
October 5, 2015
- Japan OTC Drug Market Logs 1st Rise in 5 Years: Fuji Keizai
October 5, 2015
- Mitsubishi Tanabe Wins Rights to Regeneron’s NGF Antibody in Asia
October 5, 2015
- Otsuka Files Combination Glaucoma Eye Drops in Japan
October 2, 2015
- ASKA Takes Over 2 Anti-Thyroid Drugs from Chugai
October 2, 2015
- Active Promotion of HPV Vaccines Should Be Resumed: GSK
October 1, 2015
- Mitsubishi Tanabe Raises Full-Year Earnings Projection
October 1, 2015
- Nichi-Iko Files Remicade Biosimilar in Japan
October 1, 2015
- Sato, POLA to Jointly Market Clenafin Competitor Drug
October 1, 2015
- Eisai Ups April-Sept. Profit Forecasts on Lower Sales
October 1, 2015
- Asahi Kasei Pharma Seek Japan Approval of Once-Yearly Osteoporosis Drug
October 1, 2015
- Astellas Licenses Analgesic Ion Channel Blocker from US Chromocell
October 1, 2015
- Fujifilm to Establish Cellular Dynamics Japan for iPS Biz
September 30, 2015
- CMIC Holdings CEO to Double as OrphanPacific Chairman
September 30, 2015
- Halaven Now under FDA’s Priority Review for Soft Tissue Sarcoma: Eisai
September 30, 2015
- Janssen Seeks Pediatric Use for Ultiva in Japan
September 30, 2015
- Amgen Astellas Building Sales Force before PCSK9 Approval
September 29, 2015
- GSK to Compensate for Add’l Patient Burdens Tied to Hep B Drug Shortage
September 29, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…